By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company’s instrument is far more accurate that the methods used by clinicians today – which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.

Prostate Cancer surgery is not accurate enough
Prostate cancer (PCa) is the fourth most common cancer in both sexes combined and the second most common cancer in men. In Sweden PCa is the most common cancer disease among all, and 9678 men were diagnosed with PCa in 2013 (Cancerfonden). In 2012, 1.1 million men worldwide were diagnosed with prostate cancer and 307 000 estimated deaths in 2012. The most prevalent curative treatment for PCa is radical prostatectomy (RP). In Europe, RP made up 59 % of the curative treatments in 2000 and in the USA about 70 000 men were offered RP in 2003. 1880 surgical treatments for Prostate cancer is conducted per year in Sweden, 10-20 % of these need chemotherapy afterwards due to that all cancer tissue was not removed.

Our solution
A real-time instrument to increase precision that combines two sensor methods into one small probe, combining a resonance sensor with a Raman spectroscope. The Instrument can rapidly scan the prostate surface during surgery and give the surgeon correct information about correct removal of all cancer tissue.


UBI Incubation Phase


Contact Information

Tvistevägen 48C <br /> 907 36 Umeå <br /> Sweden
Olof Lindahl, Department of Radiation Sciences/Biomedical Engineering, UmU
Kerstin Ramser, Department of Engineering Sciences and Mathematics, LTU